Psoriatic Spondyloarthritis Burden is Similar to Ankylosing Spondylitis
Psoriatic spondyloarthritis forms part of the spondyloarthritis spectrum, between peripheral-only psoriatic arthritis and ankylosing spondylitis.
Psoriasis Patients Require Annual PsA Screening
Up to 30% of psoriasis patients will develop psoriatic arthritis. Studies show that a proportion of patients in clinical care have undiagnosed PsA.
Statins with TNFa Treatment Lowers LDL levels in PsA
TNF-α inhibitor treatment in PsA, RA and AS may be associated with a significant increase in total cholesterol, triglyceridesand the atherogenic index. Statins with treatment lowered LDL levels.
ACR 2016 Pharma Reports for AS, Gout, PsA and RA
In this article, we highlight some of the most important pharma reports presented at ACR 2016 this year.
Study Shows that VLDA is Superior to other Disease Activity Measures
Redefining disease remission or inactivity examined in this assessment by Laura Coates of the University of Leeds.
Guselkumab Improves Psoriatic Arthritis in Phase 2a Study
Guselkumab significantly improved joint symptoms, physical function, psoriasis, enthesitis, dactylitis and quality of life in patients with active psoriatic arthritis, researchers report.
Apremilast vs CF101 for Psoriasis
Researchers find that apremilast and CF101 both are safe and effective for psoriasis, but apremilast outperforms CF101 through 16 weeks, until it plateaus.
Obesity's Role in the Treatment and Development of Disease
Obesity was a common theme at RNS16 this year in which speakers touched on obesity as a cause of disease onset and even as one that can prevent therapeutic treatments from working.
Adalimumab-atto: It’s Indications and Key Takeaways
In this slideshow, we summarize the newly approved indications for Amgen's new biosimilar, adalimumab-atto (Amjevita) and, we highlight key points as stated by Amgen researchers.
Biologic Switching in PsA: 5 Things Rheumatologists Need to Know
In this slideshow, we highlight five of the top concerns and questions physicians have about switching patients from one biologic to another in psoriatic arthritis.
10 Points to Consider when Evaluating your PsA Patients
Some new and old concepts to consider when evaluating patients with severe psoriatic arthritis (PsA) for cardiovascular diseases.
IL-17, IL-23 Psoriasis Pathway Inhibitors
The development pipeline for psoriasis in summary.
By clicking Accept, you agree to become a member of the UBM Medica Community.